You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

103 Results
Guidelines and Advice
Status: Current
ID: GL 17-10 v2
Version: 2
Mar 2025
Guidelines and Advice
Status: Current
ID: GL MOTAC-4
Version: 3
Jun 2025
Drug
Other Name(s): Vectibix®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jan 2025
Drug
Other Name(s): Votrient®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 2025
Drug
Other Name(s): Cytosar®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jul 2025
Drug
Other Name(s): Neulasta®, Lapelga®, Fulphila™; Ziextenzo®; Nyvepria™, Niopeg®, Pexegra™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2025
Drug
Other Name(s): Caelyx®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2025
Drug
Other Name(s): Pomalyst®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Apr 2025
Drug
Other Name(s): Iclusig®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 2025
Drug
Other Name(s): Keytruda®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2025
Drug
Other Name(s): Ibrance™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Oct 2025
Regimen
Cancer Type:
Gynecologic, 
Ovary
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Liposomal DOXOrubicin - Single Agent Treatment of Platinum Sensitive Ovarian Fallopian Tube or Primary Peritoneal Cancer
New Drug Funding Program
    Liposomal Doxorubicin - Platinum-Resistant Ovarian Fallopian Tube or Primary Peritoneal Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pegylated liposomal DOXOrubicin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025

Pages